Business Wire

Magnitude Introduces Cloud-Scale Business Insights for ERP Systems

Share

Magnitude Software, provider of continuous intelligence for the data-driven enterprise, today announced the release of Magnitude Angles Cloud, a cloud-based version of the company’s Angles process analytics solution. Angles Cloud greatly accelerates the delivery of powerful business insights from SAP and Oracle ERP systems directly to operational leaders in finance, supply chain, manufacturing and distribution, enabling them to make faster, more effective business decisions.

Traditional business intelligence reporting requires custom development by teams of data scientists, skilled in translating the complex data schema of ERP systems, to build reports consumable by business users. Magnitude Angles provides a context-rich business data model that abstracts this complexity and includes thousands of pre-configured templates and reports to put operational analytics in the hands of business users.

By eliminating the need for time-consuming custom development to provide near real-time business insights, business users can now make decisions quickly without having to rely on a data scientist to prepare and translate reports. The core Angles data model can also be connected to leading business intelligence (BI) tools, providing a “business brain” for these platforms that speeds report creation and effectiveness.

“It is often a challenge to easily get information out of SAP in a report format,” said Steve Hankins, CFO for Morgan Foods International, the largest private label soup manufacturer in the US. “Angles for SAP creates an abstraction layer for reporting that Morgan Foods has made extensive use of over the years and is embedded in the way we do things today. We’ve got a lot of business processes built around Angles. Because of that, we never considered implementing SAP S/4HANA without Angles. Our upgrade simply would not have been as successful without it.”

Angles Cloud combines the power of enterprise process analytics with the scale, performance and deployment speed of cloud. As a self-service, cloud-based solution, it can begin offering insights within a single day – far faster than any comparative on-premises process analytics platform.

“Angles Cloud is a significant milestone in allowing businesses to consume insights and increase an organization’s competitiveness,” said Jeffrey Shoreman, CEO for Magnitude. “Business insights are available at cloud speed, enabling customers to better anticipate supply chain disruptions, capture additional savings on their payment terms, and out-think and out-maneuver the competition.”

“We are excited to gain better insight into our supply chain, stock accounting and financial processes by adopting Magnitude Angles,” said Hans Platschorre, CFO for Hans Anders, a leading European optical retailer. “Angles Cloud will provide the value of self-service process analytics in a fast, secure and resilient cloud environment.”

Magnitude Angles empowers the data-driven enterprise to:

  • Deliver deep insights and improved business outcomes through more than 2,000 industry-tailored, no-code business reports
  • Transform ERP data into a source of continuous intelligence for real-time decision making across business functions
  • Reduce the time-to-value of business analytics
  • Improve BI projects with integrations to speed report development

Angles Cloud adds:

  • Rapid deployment shortens time-to-insight to a single business day
  • Cloud scale, elasticity and resilience
  • Ability to deploy adjacent to cloud-based ERP landscapes and data warehouses for greater performance

To learn more or to request a demo, visit: https://www.magnitude.com/products/process-analytics

About Magnitude Software

Data is the fuel that powers the modern enterprise. Our mission is to help companies turn their core business data into continuous intelligence, providing actionable insights to shorten the path from data to decision. We enable our customers to connect data across enterprise applications and business processes including supply chain, finance and order management. Our relentless focus on innovation, customer experience and solving business problems is why more than 1,300 enterprises around the world trust Magnitude to put the power of their data into the hands of their business users. For more information visit magnitude.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Ashley Paula-Legge
Big Valley Marketing for Magnitude Software
magnitudepress@bigvalley.co

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 14:00:00 EET | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreement were not disclosed. “This new agreement builds upon our recent co-development collaboration with Acepodia, which has focused on the evaluation and selection

Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 12:08:00 EET | Press release

Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played

Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 11:44:00 EET | Press release

At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will

Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 11:00:00 EET | Press release

Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE. “Insurance is an industry where the stakes of using AI are particularly high: the decisions can affect millions of people. Allianz and Anthropic both take that very seriously, and we look forward to working together to make insurance better for those w

MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 08:00:00 EET | Press release

MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind, placebo-controlled study designed to confirm the promising efficacy signals and favorable safety profile previously observed in MH002’s Phase 2a studies. MH002, a rationally designed live microbial consortium, is the most advanced Live Biotherapeutic Product (LBP) of its kind, targeting disease-specific mechanisms through a synergistic combination of

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye